دورية أكاديمية
Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV® Active Ingredients
| العنوان: | Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV® Active Ingredients |
|---|---|
| المؤلفون: | Camille Jacques, Flora Marchand, Mathias Chatelais, Adrien Brulefert, Ilaria Floris |
| المصدر: | Life, Vol 14, Iss 1, p 102 (2024) |
| بيانات النشر: | MDPI AG, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Science |
| مصطلحات موضوعية: | micro-immunotherapy, Epstein–Barr virus, cytokines, immunotherapy, interleukin-2, EBV-associated diseases, Science |
| الوصف: | Background: Epstein–Barr virus (EBV) is often kept silent and asymptomatic; however, its reactivation induces a chronic and/or recurrent infection that is associated with numerous diseases, including cancer and inflammation-related disorders. As no specific treatment is currently available, the immune factors-based micro-immunotherapy (MI) medicine 2LEBV® could be considered a valuable therapeutic option to sustain the immune system in EBV reactivation. Methods: The present work aimed to investigate, for the first time, the effect of 2LEBV® in several in vitro models of uninfected immune-related cells. Results: 2LEBV® displayed phagocytosis-enhancing capabilities in granulocytes. In human peripheral blood mononuclear cells (PBMCs), it increased the intra- and extra-cellular expression of interleukin (IL)-2. Moreover, it modulated the secretion of other cytokines, increasing IL-4, IL-6, and tumor necrosis factor-α levels or lowering other cytokines levels such as IL-9. Finally, 2LEBV® reduced the expression of human leukocyte antigen (HLA)-II in endothelial cells and macrophages. Conclusions: Although these data are still preliminary and the chosen models do not consider the underlying EBV-reactivation mechanisms, they still provide a better understanding of the mechanisms of action of 2LEBV®, both at functional and molecular levels. Furthermore, they open perspectives regarding the potential targets of 2LEBV® in its employment as a therapeutic intervention for EBV-associated diseases. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2075-1729 26321831 |
| العلاقة: | https://www.mdpi.com/2075-1729/14/1/102Test; https://doaj.org/toc/2075-1729Test |
| DOI: | 10.3390/life14010102 |
| الوصول الحر: | https://doaj.org/article/bb97452c74f84e2ba263218314e93abdTest |
| رقم الانضمام: | edsdoj.bb97452c74f84e2ba263218314e93abd |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20751729 26321831 |
|---|---|
| DOI: | 10.3390/life14010102 |